Mr. Patel has more than 19 years of experience in the biopharmaceutical industry. Prior to OncoMed, Mr. Patel held executive roles with multiple biotechnology companies, including BiPar Sciences, Connetics Corporation and Abgenix, Inc. He has played a leadership role in driving more than $8 billion in strategic licensing and M&A transactions, including leading OncoMed's strategic transactions with Bayer and Celgene and managing the collaborative efforts with GSK. Earlier in his career, he was a management consultant with McKinsey & Company. He currently serves on the Board of Directors and is a member of the audit committee of Ligand Pharmaceuticals, Inc. Mr. Patel holds a B.S. in Chemistry from the University of California, Berkeley, and an M.S. in Molecular Biotechnology / Bioengineering from the University of Washington.
"Sunil has played a critical role here at OncoMed for the last five years. In structuring our collaborations and overseeing our alliances, he has significantly contributed to the company's operations and the management of financial resources. Sunil's deep understanding of our business and the industry position him well for success in this expanded role," said Mr. Hastings. "On behalf of OncoMed's Board of Directors and the entire company, I want to thank Will for his significant contribution to OncoMed's success over the past seven years. We all wish him the best as he takes on a new opportunity with a private company."
Anticipated 2014 Milestones and Guidance
Upcoming clinical milestones include the following:
- Initiate the randomized Phase 2 portion of the ALPINE and PINNACLE clinical trials of OMP-59R5 in pancreatic cancer and small cell lung cancer, respectively
- Begin randomized Phase 2 clinical studies of demcizumab in non-small cell lung cancer and pancreatic cancer
- Complete patient enrollment in the ongoing Phase 1a clinical studies of vantictumab and OMP-54F28
- File an Investigational New Drug (IND) application with the US Food and Drug Administration for OMP-305B83 (anti-DLL4/anti-VEGF bispecific)
- Present clinical and preclinical data at upcoming scientific and medical conferences
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts